Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib long-term extension study in patients with solid tumors
NL-OMON41205Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dovitinib in Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Adverse events. Planned start Jul 2014; status: withdrawn.
02
Drugs
dovitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON41205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41205.